136247-07-9

Basic information

• Product Name: 5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine (Rotigotine)
• Synonyms: 5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine (Rotigotine);1,2,3,4-Tetrahydro-5-methoxy-N-(phenylmethyl)-2-naphthalenamine;1,2,3,4-Tetrahydro-5-methoxy-N-propyl-2-naphthalenamine
• CAS NO: 136247-07-9
• Molecular Formula: C₁₈H₂₁NO
• Molecular Weight: 267.37
• Product Categories: APIs Intermediate
• Mol File: 136247-07-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 424.4 °C at 760 mmHg
• Flash Point: 176.6 °C
• Appearance: /
• Density: 1.09 g/cm³
• Vapor Pressure: 2.07E-07mmHg at 25°C
• Refractive Index: 1.593
• CAS DataBase Reference: 5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine (Rotigotine)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine (Rotigotine)(136247-07-9)
• EPA Substance Registry System: 5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine (Rotigotine)(136247-07-9)

Safety Data

• Hazardous Substances Data: 136247-07-9(Hazardous Substances Data)

Usage

General Description

Rotigotine is a chemical compound that falls under the category of dopamine agonists. It is used as a medication for the treatment of Parkinson's disease and restless legs syndrome. The chemical structure of rotigotine consists of a 5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine. 5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine (Rotigotine) acts as a dopamine receptor agonist, specifically targeting the D2, D3, and D4 dopamine receptors in the brain. By stimulating these receptors, rotigotine helps to alleviate the motor symptoms of Parkinson's disease, such as tremors, stiffness, and slow movements, as well as reduce the symptoms of restless legs syndrome. It is typically administered as a transdermal patch for continuous delivery of the medication over a 24-hour period.

InChI:InChI=1/C18H21NO/c1-20-18-9-5-8-15-12-16(10-11-17(15)18)19-13-14-6-3-2-4-7-14/h2-9,16,19H,10-13H2,1H3

Upstream product

• 3900-49-0 1,6-dimethoxynaphthalene 
• 575-44-0 1,6-dihydroxynaphthalene 
• 32940-15-1 5-methoxy-2-tetralone 
• 100-46-9 benzylamine 

Downstream Products

• 58349-24-9 C₈H₈O₃*C₁₈H₂₁NO 
• 136247-11-5 N-((S)-5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-2-(4-nitro-phenyl)-N-propyl-acetamide 
• 136247-11-5 N-((R)-5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-2-(4-nitro-phenyl)-N-propyl-acetamide 
• 136316-06-8 (S)-(-)-2--5-methoxytetralin 
• 136316-05-7 (R)-(+)-2--5-methoxytetralin 
• 129388-80-3 (S)-(-)-2--5-hydroxytetralin 
• 129388-77-8 (R)-(+)-2--5-hydroxytetralin 
• 101403-24-1 (S)-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propylamine hydrochloride 
• 101403-25-2 (R)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-amine 
• 58349-23-8 (S)-(-)-2-(N-benzylamino)-5-methoxytetralin 
• 58349-20-5 (R)-(+)-2-(N-benzylamino)-5-methoxytetralin 
• 4018-91-1 2-Amino-5-methoxy-1,2,3,4-tetrahydronaphthalene 
• 58349-21-6 C₈H₈O₃*C₁₈H₂₁NO 

Relevant articles and documents

Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands

The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen compounds of general formula (I) and (Iprot), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals, mediated by the receptor 5-HT7 affinity.

Combination of a 5-HT7 receptor ligand and an opioid receptor ligand

The present invention refers to a combination of a 5HT7 receptor ligand and an opioid recptor ligand, especially of a 5HT7 receptor agonist and an opioid recptor agonist, a medicament comprising this combination, or the use of this combination for the treatment of the symptoms of pain, the prevention or the prophylaxis of the symptoms of pain.

2-Amido-8-methoxytetralins: A Series of Nonindolic Melatonin-like Agents

A series of unsubstituted and methoxy-substituted 2-amidotetralins (4a-q) was prepared and evaluated for their ability to complete for 2-iodomelatonin binding to chicken retinal membranes and for their potency to inhibit the calcium-dependent release of dopamine from rabbit retina.The lead compound, 2-acetamido-8-methoxytetralin (4j), showed a moderate affinity (Ki = 46 nM) and potency (IC50 = 1.4 nM) at the melatonin receptor.The structural requirements necessary for optimal agonistic activity at the melatonin receptor are as follows.First, the amido group, which should have a small, nonbranched alkyl group, is essential for affinity, and second, the methoxy substituent at the 8-position of the 2-amidotetralin ring is essential for optimal agonistic activity at the melatonin receptor.We concluded that this series of unsubstituted and methoxy-substituted 2-amidotetralins constitutes a class of nonindolic melatonin-like agents that can be used as pharmacological tools to further characterize melatonin receptors and to elucidate the mode of action of melatonin.